Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01750554
Other study ID # 10-00524D
Secondary ID
Status Completed
Phase N/A
First received December 10, 2012
Last updated April 9, 2015
Start date December 2012
Est. completion date July 2013

Study information

Verified date April 2015
Source University of California, San Francisco
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The investigators are proposing to continue investigation to improve the accuracy of the SpHb (continuous hemoglobin monitoring device) by administering an intermediate acting digital nerve block in the finger connected to the SpHb, specifically bupivacaine 0.25% in patients undergoing spine surgery. Bupivacaine is FDA approved and in routine use.


Description:

Patients undergoing spine surgery will be randomized to receive (or not) the bupivacaine digital block on the finger attached to the new limited release version of the hemoglobin sensor, RevG. The SpHb reading will be compared to a blood hemoglobin level analyzed in the UCSF Clinical Laboratories.


Recruitment information / eligibility

Status Completed
Enrollment 19
Est. completion date July 2013
Est. primary completion date July 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria:

- Male or female 18 years of age or older

- American Society of Anesthesiologists classification 1, 2 or 3

- Scheduled to undergo spine or hip surgery

Exclusion Criteria:

- Pregnant or nursing

- Patients who in the study investigators clinical judgement would not be suitable

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms

  • Patients Undergoing Spine Surgery

Intervention

Other:
intermediate-acting digital nerve block
non-therapeutic Bupivacaine digital nerve block to assess effect on accuracy of diagnostic readings

Locations

Country Name City State
United States University of California, San Francisco San Francisco California

Sponsors (1)

Lead Sponsor Collaborator
University of California, San Francisco

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary SpHb (continuous hemoglobin monitor reading) minus tHb (clinical laboratory determined hemoglobin value). Use of a longer acting local anesthetic (bupivacaine) for the digital nerve block will result in SpHb (the non-invasive hemoglobin device) being sufficiently accurate for blood transfusion decisions(= 1.0 g/dL difference)
To assess if using an intermediate-acting digital nerve block will improve the accuracy of the SpHb readings when compared to a blood hemoglobin level analyzed in the UCSF Clinical Laboratories intermittently during the patient's surgery.
Intermittent (about hourly) hemoglobin checks throughout the surgery. No
See also
  Status Clinical Trial Phase
Recruiting NCT03644407 - Galeazzi Spine Surgery RegistryGaleazzi Spine Registry: Prospective Study for Clinical Monitoring
Completed NCT01877876 - Assessing the Accuracy of the RevK Sensor N/A
Completed NCT04994704 - Comparison of Postoperative QoR-15 Scores Between Propofol and Remimazolam N/A